Get the app
US › Healthcare

InMed Pharmaceuticals Inc (INM)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$15.56+17.79%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit
$-2.3M
EPS
$-0.36

Key statistics

Market cap
$9.6M
Forward P/E
0.0
P/B
8.59
Book value
$0.20
EPS (TTM)
$-27.60
52-week high
$23.30
52-week low
$5.75
50-day MA
$1.39
200-day MA
$1.21
Beta
0.99

Analyst view

with an average price target of $20.00.

Shareholding

Insiders
0.06%
Institutions
53.49%

Largest institutional holders

FundStake
ADAR1 Capital Management LLC14.56%
Vivo Capital, LLC14.53%
Squadron Capital Management LLC5.92%
Ikarian Capital, LLC4.46%
Ursa Fund Management, LLC2.29%
Suvretta Capital Management, LLC1.82%
BOOTHBAY FUND MANAGEMENT, LLC1.35%
Sabby Management LLC0.82%

Corporate actions

ActionDetailDate
Split1 : 10
effective Nov 5, 2026		2026-11-05

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InMed Pharmaceuticals Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.